Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain

Next Previous
X
Search
Trial Profile

Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 29 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Jun 2018 According to results published in the Obstetrics and Gynecology Journal, secondary outcomes also included pain scores at rest at 24, 48, and 72 hours postoperatively as well as pain scores with movement at 24 and 72 hours.
    • 06 Jun 2018 Primary endpoint (Pain score with activity at 48 hours postoperatively: Liposomal bupivacaine versus Placebo) has not been met, according to results published in the Obstetrics and Gynecology Journal.
    • 06 Jun 2018 Results published in the Obstetrics and Gynecology Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top